Wednesday, 29 July 2026

Indian corporate news, decoded into deal flow

NSE LIVE
NIFTY 50 INDIA VIX
as of
MARKETS
DEAL FLOW
Gland Pharma Receives US FDA Approval… ▲ Market News / Economy Renaissance Global Expands U.S. Retail Presence… ▲ Capex & Future Plans Shyam Metalics Commissions ₹150 Crore Beneficiation… ▲ Capex & Future Plans Vardhman Special Steels Highlights Strong Q1… ▲ Capex & Future Plans Magellanic Cloud Subsidiary Bags $1.21 Million… ▲ Order Book Manipal Health IPO 2026: Issue Details,… ▲ Ipos Car trade Tech Limited Partners With… ▲ Capex & Future Plans
Home / Company Results / BIOCON Q2 Results: Revenue rose by 3.00% year-over-year (YoY) to Rs. 3590 crore, while net profit declined by 85.00% YoY to Rs. 27 crore.
RS · Company Results

BIOCON Q2 Results: Revenue rose by 3.00% year-over-year (YoY) to Rs. 3590 crore, while net profit declined by 85.00% YoY to Rs. 27 crore.

NSE: BIOCON: Rs.320.40(-2.02%)

Biocon is engaged in the business of manufacture of biotechnology products and research services.

Revenue

Revenue for the current quarter (Sep 2024) is Rs. 3590 crore which is Rs. 3433 crore more than the revenue in the previous quarter (Jun 2024). However, it is higher than the revenue for the same quarter last year (Sep 2023) which was Rs. 3462 crore.

Net Profit

Net Profit for the current quarter (Sep 2024) is Rs. 27 crore, which is Rs. 862 crore less than the net profit in the previous quarter (Jun 2024). However, compared to the same quarter last year, it is significantly lower than the net profit of Rs. 173 crore for Sep 2023.

Other Income

Other income for the current quarter (Sep 2024) is Rs. 58 crore, which is Rs. 1166 crore less than the other income for the previous quarter (Jun 2024). However, compared to the same quarter last year, it is lower than the other income of Rs. 134 crore for Sep 2023.